SNCA and Parkinson disease: In rotenone-induced rat and zebrafish PD models, SLN preparations encapsulating neuroprotective compounds exhibited increased motor coordination, suppression of oxidative markers such as malondialdehyde, recovery of antioxidant enzyme activity, and suppression of α-synuclein aggregation with controlled release, stability, and biodegradability [174].